A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
about
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsThe effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory studyAscomycins: promising agents for the treatment of inflammatory skin diseases.New approaches to topical therapy.What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?Therapeutic options for chronic hand dermatitis.What's new in atopic dermatitis?Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.New treatments for atopic dermatitis.International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies.Pimecrolimus: a review.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In VitroPsoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.Macrolactam immunomodulators (tacrolimus and pimecrolimus): new horizons in the topical treatment of inflammatory skin diseases.The role of topical calcineurin inhibitors in atopic dermatitis.Pimecrolimus -- an anti-inflammatory drug targeting the skin.Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Problem-based learning: a review of current issues relevant to physiotherapy education.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: a prospective case series--a non-controlled, open-label study.Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?Topical therapies for pruritus.Management of sulfur mustard-induced chronic pruritus: a review of clinical trials.Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.Randomized controlled studies on the efficacy of antiarthritic agents in inhibiting cartilage degeneration and pain associated with progression of osteoarthritis in the rat.Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.Four cases of facial discoid lupus erythematosus successfully treated with topical pimecrolimus or tacrolimus.Pimecrolimus reduces eosinophil activation associated with calcium mobilization.Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial.The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.First experience of topical SDZ ASM 981 in children with atopic dermatitis.SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils.
P2860
Q24675365-F792929B-5DB5-40B3-B124-0628AD269E56Q28302046-3D9812D8-A6EE-46E4-B02D-A006CCA579AEQ34074668-744009AA-2C68-45A3-96DE-24AEF5FD2C03Q34106948-CD0E3350-B78D-4D7E-8727-2007175DB72EQ34190563-561EC248-A189-4047-9129-61CB0CE78BF6Q34325706-2A6F30B3-0A30-4151-99CA-28FD76113259Q34352747-12BBBABE-8FAC-40B6-8679-C824E8783E65Q34552586-6CDF6EB9-4F9A-47A7-8021-0FCCD0A0F824Q34592295-EF7F3FA6-0C7B-4CF0-BB05-250B5D08CCAEQ35106685-82A8D4FA-190C-4041-A463-0E6949A25784Q35206755-44E2BFFB-3CA5-4F13-958D-D1B71A960518Q35809490-8C8E1CE9-227F-476F-B120-12D1A0F3474BQ35839772-B241E6ED-2C66-418C-8542-74BEFA456A71Q35843827-0AA2C9D9-83CD-4FC2-B721-CD016007F84BQ35922000-E0D854AE-2B84-4812-BBE4-05FF0A311719Q35952647-60981546-BB62-4CDD-9CF7-BDC81BC67C70Q35961095-B0EB7575-0555-4EDC-9DED-4E25825BB02AQ36179870-3B0D9CEC-A0DA-4F49-86B5-0DBC8F5F4476Q36222741-7E29BB54-7CD8-439D-A2A9-8D42EA66B763Q36356956-95239B40-2D4A-4CF8-97F6-053D77752B52Q36574341-B0AFB30E-D745-46FF-B22E-366DF3EC8CC1Q36648456-6A36681F-4254-4313-B4E8-1D71F5FF6BF4Q36681795-88F7417E-0EDA-4969-8A11-B74F98C48966Q36861654-FDD7F89E-AD00-4772-BD0E-E45164B049B4Q37049981-5356B55E-EC13-47EC-A0C0-D93873979EE1Q37622487-3E97D3B0-1504-4382-91DB-157A468F55D8Q37902324-2C16968E-508E-42A5-B3F6-4DA95215EA01Q37956413-BD0AD2C7-9081-4FED-AC3C-6962877E38CBQ38084638-CEE1D6BB-F07E-48F6-8D1B-23B2D9E0507AQ38123240-DF9EE588-3A95-488C-92D9-CC85E895BAB0Q38800946-A29A7D4F-8FB8-40F2-8192-9BFA596E1B75Q39355978-78CB6AEC-1486-4D48-B68D-F7F49E687E86Q41771409-C9752127-4277-4976-8E4B-97DED953AF33Q42643465-14F8693B-3DF8-4110-902B-0BB4DB4A1E1AQ42668620-3F5D0AAD-ED3E-4557-AEDA-BE53A653E548Q43548628-9FDB9F12-6453-4BB8-A20F-40DF55D56E06Q43572230-7155DDF9-2682-4AFC-A2F0-B9D4C9B5A316Q43572233-7D74BEA5-177D-495F-8B3C-54A118D4FF74Q44150677-06A78428-3B4E-4203-A91A-B3B16A64EB89Q44340018-07801C6F-7230-4355-8952-3CDCC62CB8B7
P2860
A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@ast
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@en
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@nl
type
label
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@ast
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@en
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@nl
prefLabel
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@ast
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@en
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@nl
P2093
P2860
P1476
A novel anti-inflammatory drug ...... iseases: in vitro pharmacology
@en
P2093
F J Werner
F Kalthoff
M Grassberger
P Hiestand
T Baumruker
P2860
P304
P356
10.1046/J.1365-2133.1999.02974.X
P407
P577
1999-08-01T00:00:00Z